Figure 1.

Recurrence-free intervals (RFIs) in melanoma patents following conventional therapeutic strategies. Before inclusion into the trial, most patients had a stage IV metastatic disease history of at least one episode where all disease disappeared following standard therapies and/or was grossly resected, but recurred over time. The duration of each RFI is given in months. Consistent with published data, the median RFI was 6 months. Note, that patients #1, #2, #6, and #9 experienced several of these episodes, patient #7 experienced none.